Thozhukat Sathyapalan

Thozhukat Sathyapalan

Hull York Medical School - York / United Kingdom
Medical and Health Sciences / Endocrinology and Metabolism
AD Scientific Index ID: 1145708
person_outline Thozhukat Sathyapalan's MOST POPULAR ARTICLES
1-) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ...The Lancet 394 (10193), 121-130, 201916122019
2-) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trialCW Le Roux, A Astrup, K Fujioka, F Greenway, DCW Lau, L Van Gaal, ...The Lancet 389 (10077), 1399-1409, 20175392017
3-) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialRECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ...MedRxiv, 2021.06. 15.21258542, 2021485*2021
4-) Molecular mechanisms linking oxidative stress and diabetes mellitusH Yaribeygi, T Sathyapalan, SL Atkin, A SahebkarOxidative medicine and cellular longevity 2020 (1), 8609213, 20206372020
5-) Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialHC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ...The Lancet 394 (10193), 131-138, 20196042019